Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 5ofatumumab 4Imatinib Mesylate 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Rituximab 3Cyclophosphamide 3ruxolitinib 2obinutuzumab 2Sirolimus 2Mycophenolic Acid 2KW-2478 2Filgrastim 2Alemtuzumab 2posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1milatuzumab 1lonafarnib 1fenebrutinib 1abexinostat 1Whole-Body Irradiation 1Voriconazole 1Vision, Ocular 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × Vision, Ocular × Other hematologic neoplasm × Clear all
NCT02085798 2020-01-27

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Celgene

Completed
503 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡